Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
ROBIN J SHATTOCK · IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE · 2024 · $344,112 — Abstract/summary There is currently no vaccine in clinical use to combat group A streptococcal infection, despite the considerable global burden of acute and chronic disease attributable to this pathogen. The long-term goal of this work is the development of a combination vaccine that can combat gro…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $1,582,499 — ABSTRACT OVERALL The main goal of our IPCAVD Program grant is to evaluate in humans self-amplifying mRNA (saRNA) vaccines that express two HIV-1 Env-derived protein immunogens that activate and initiate the maturation of VRC01-class B cell receptors (BCRs). The first immunogen, 426c.Mod.Core, was sp…
Dipak Kumar Raj · UNIVERSITY OF SOUTH FLORIDA · 2024 · $375,000 — Project Summary The overall aim of this application is to advance PfCDPK5 and PfGARP as vaccine candidates for falciparum malaria. P.falciparum malaria affects almost one-half of the world's population and causes more than 500,000 deaths annually. Young children in malaria endemic areas of Africa h…
Genoveffa Franchini · DIVISION OF BASIC SCIENCES - NCI · 2024 · $249,755 — HTLV-1A is the most common form of HTLV-1 worldwide and causes leukemia and inflammatory diseases such as the neurodegenerative HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). HTLV-1C, first genetically characterized in Melanesia in the early 1990s, is endemic in indigenous Aust…
Patrick Duffy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,649,684 — From our publications this year, we report the following advances in FY2024: 1. Duffy PE, Gorres JP, Healy SA, Fried M. Malaria Vaccines: A New Era. 2024. Nature Reviews Microbiology. Jul 18. doi: 10.1038/s41579-024-01065-7. In this major review article, we provided an overview of the malaria probl…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2024 · $2,399,995 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
Siyuan Ding · WASHINGTON UNIVERSITY · 2024 · $155,500 — Project Summary Diarrheal diseases account for 1 in 10 child deaths worldwide. Rotavirus (RV) and enterotoxigenic Escherichia coli (ETEC) are major etiological causes of acute gastroenteritis and severe diarrhea worldwide, together resulting in approximately 300,000 deaths each year, mostly in chil…
Elias Sayour · UNIVERSITY OF FLORIDA · 2024 · $597,571 — Project Summary Immunotherapy has shown profound benefit for adult patients but has yet to be fully unlocked for pediatric solid tumors such as osteosarcoma (OSA) where a significant percentage of children/adolescents succumb due to the presence of lung metastasis. OSA, like many poorly tumor immuno…
Michael S Diamond · WASHINGTON UNIVERSITY · 2024 · $46,715,173 — SUMMARY. The Flavivirus and Alphavirus ReVAMPP (FLARE) Center will develop and optimize protein nanoparticle, virion-based, and mRNA vaccine platforms, and monoclonal antibody (mAb)-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. A key goal is t…
Eleftherios Michailidis · EMORY UNIVERSITY · 2024 · $195,625 — Project Summary There are approximately a quarter of a billion people worldwide chronically infected with hepatitis B virus (HBV) who are at risk of developing liver cirrhosis and hepatocellular carcinoma. The loss of life due to HBV-related complications each year is about 820,000 people. At the sa…
SAAD BHAMLA · GEORGIA INSTITUTE OF TECHNOLOGY · 2024 · $263,399 — Project Summary/Abstract Given modern history’s advancements in molecular biology, from the exponential decrease in the costs of genome sequencing, nucleotide synthesis, and genome editing (CRISPR), synthetic biology is poised to be the next major revolution in technological advancements. The White …
Alkesh Harihar Jani · VA EASTERN COLORADO HEALTH CARE SYSTEM · 2024 — Bacterial infections are the second leading cause of death in ESRD. The incidence of pneumonia amongst dialysis patients is increasing and leads to a mortality rate that is 14-16-fold greater than pneumonia in the general population. Little is known regarding the immune response to pneumococcal vacc…
Rhiju Das · STANFORD UNIVERSITY · 2024 · $684,690 — PROJECT SUMMARY The continuing discoveries of RNAs and their critical roles in cellular and viral machinery are inspiring novel antibacterial, antitumor, antiviral, and genome-editing therapies based on disabling, manipulating, and repurposing the RNAs involved. Unfortunately, our poor biophysical u…
Ken A Halvorsen · STATE UNIVERSITY OF NEW YORK AT ALBANY · 2024 · $430,375 — Project Summary Our vision is to develop, apply, and advance new technologies in the broad thematic program of the manipulation of nucleic acids. The research largely focuses on RNA-based applications, which is both driven and enhanced by our unique environment at The RNA Institute, enabling easy co…
Yang Xu · LUNA LABS USA, LLC · 2024 · $903,639 — Project Summary Significant research has gone into the development of a safe and effective vaccine for HIV-1. Although many strategies have been attempted; none has been successfully established. Even a partially effective vaccine could decrease the number of people who are infected with HIV, furthe…
ERIC T. KOOL · STANFORD UNIVERSITY · 2024 · $12,184 — Summary of parent project (R35 GM145357) Work in the last decade from many labs has underlined the critical importance of RNA-mediated cellular pathways, and clear connections of specific RNAs to human health. RNAs are increasingly viewed both as appealing therapeutic targets, and as therapeutic age…
Nerea Zabaleta · SCHEPENS EYE RESEARCH INSTITUTE · 2024 · $668,569 — SUMMARY/ABSTRACT Broadening the spectrum of vaccine platforms that confer protective, durable and broad immunogenicity is important for pandemic preparedness. Here, we aim to create essential preclinical data to characterize a novel genetic vaccine platform called PARVAX to increase its clinical acc…
Kay Lynn Medina · MAYO CLINIC ROCHESTER · 2024 · $318,000 — PROJECT SUMMARY Steady-state hematopoiesis in bone marrow is critical for maintenance of blood cell genesis and immune competence throughout life. Concomitant with aging, the bone marrow hematopoietic stem cell (HSC) compartment undergoes cell intrinsic and extrinsic changes that biases hematopoieti…
David E Verhoeven · IOWA STATE UNIVERSITY · 2024 · $225,370 — PROJECT SUMMARY / ABSTRACT Highly pathogenic and low pathogenic strains of avian influenza continue to circulate and infect birds in Asia with occa- sional spread into the North American flyway. These necessitate the culling of any poultry farms that test positive for these strains. Furthermore, th…
STEPHEN K BURLEY · RUTGERS, THE STATE UNIV OF N.J. · 2024 · $3,880,000 — The Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) works with community stakeholders to preserve and deliver rigorously-validated, expertly-biocurated, three-dimensional (3D) biostructure information archived in the Protein Data Bank (PDB) to many millions of Depos…